Minerva Neurosciences Inc (NERV) News & EventsNERVMinerva Neurosciences Inc

Minerva Neurosciences to Initiate Phase 3 Trial for Roluperidone

"Strengthened by the recent financing and our general alignment with the U.S. Food and Drug Administration ("FDA") on trial design, we are working towards initiation of the confirmatory Phase 3 trial with roluperidone for the treatment of negative symptoms of schizophrenia in the second quarter," said Dr. Remy Luthringer, Chairman and CEO of Minerva Neurosciences. "With the $80 million upfront proceeds and the exercise proceeds from the Tranche A warrants, we anticipate sufficient funds to complete the Phase 3 trial and resubmission of the New Drug Application ("NDA") ahead of the launch of roluperidone in the United States, if approved."

Dow and S&P Futures Dip Marginally, Nasdaq Flat

In the opening hour of the evening session, equity futures are down marginally, with Dow Industrials and S&P e-minis off by a decimal while Nasdaq 100 contract is trading flat.  In commodities, WTI Crude Oil is little changed after API inventory data saw its first build in multiple weeks, while precious metals have broken out to fresh record highs - Gold above $4,525 and Silver approaching $72 per ounce.Treasuries traded mixed with conflicting data in the form of much stronger than expected Q3 GDP and a much more recent cautionary story from December Conference Board Consumer Confidence report, which fell to its lowest level since the "tariff tantrum" in April - the yield on the 10-year Treasury ended around 4.17% after reaching 4.20% earlier.New record high close in the S&P 500 index was paced by Communication Services and Technology sectors, while Staples lagged once again.  Nvidiawas especially strong with a 3% advance, though the stock still trades off by over 10% from its highs in October.  Alphabetas well as Amazonalso notched respectable gains of about 1.5%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Limoneiraup 0.9%ALSO HIGHER -Ramaco Resourcesup 6.7% after announcing $100M buybackUiPathup 3.7% after admission into S&P MidCap 400DOWN AFTER EARNINGS -Good Times Restaurantsdown 1.5%ALSO LOWER -Minerva Neurosciencesdown 3.9% after selling stock for holdersOrganogenesis Holdingsdown 3.4% after initiating rolling submission of BLA to FDA for ReNu